Drugs / 3-hydroxybutyrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04656236 | Jan 2021 → Mar 2022 | diabetic ketoacidosis, type 1 diabetes mellitus | University of Aarhus | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3-hydroxybutyrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04656236 ↗ |
| Known as | 3-OHB | “The ketone body 3-hydroxybutyrate (3-OHB) inhibits lipolysis in healthy individuals.” PMID 40210728 ↗ Apr 2025 |
| Route | Intravenous | “3 hours of continuously intravenous infusion of 3-hydroxybutyrate.” NCT04656236 ↗ |